Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Creteil – page 10

634 clinical trials in Creteil, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Creteil at a glance
634
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

634 trials in Creteil

Open in trial search

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study of DNTH103 Treatment for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: Comparing Effectiveness with Placebo

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dnth103
  • Sponsor:Dianthus Therapeutics Inc.

Schizophrenia

Recruiting

Study on Brain Inflammation in Schizophrenia Patients Using 18F-DPA-714

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:N,N-Diethyl-2-(2-(4-(2[(18)F]-Fluoroethoxy)Phenyl)5,7Dimethylpyrazolo[1,5A]Pyrimidin-3-Yl)Acetamide
  • Sponsor:Inserm

Huntington's disease

Recruiting

Study on [18F]MNI-659 to Track Huntington's Disease Progression in Symptomatic and Pre-symptomatic Patients

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:2-[2-[3-[4-(2-(18F)FLUORANYLETHOXY)PHENYL]-7-METHYL-4-OXOQUINAZOLIN-2-YL]ETHYL]-4-PROPAN-2-YLOXYISOINDOLE-1,3-DIONE
  • Sponsor:Assistance Publique Hopitaux De Paris

Crohn's disease

Recruiting

Study on Fecal Microbiota Transplantation for Crohn's Disease Patients in Remission After Stopping Anti-TNF Therapy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Placebo
  • Sponsor:Assistance Publique Hopitaux De Paris

Pathogen resistance

Recruiting

Study of Oral Fecal Microbiota Transplantation in Patients Colonized with Multi-Drug Resistant Bacteria

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Placebo
  • Sponsor:Assistance Publique Hopitaux De Paris

Peripheral T-cell lymphoma unspecified+1

Recruiting

Study on Azacitidine, Roginolisib, and Golcadomide for Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:LYSARC

Pancreatic carcinoma

Recruiting

Study on Chemotherapy for Patients with Resected Pancreatic Cancer Using FOLFIRINOX and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Centre Hospitalier Universitaire Rouen

Small cell lung cancer extensive stage

Recruiting

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Gilead Sciences Inc.

Blastic plasmacytoid dendritic cell neoplasia

Recruiting

Study on the Effectiveness and Safety of Tagraxofusp and Venetoclax for Adults with Untreated Blastic Plasmacytoid Dendritic Cell Neoplasm

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:TAGRAXOFUSP
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Sickle cell disease

Recruiting

Study on Rilzabrutinib for Patients Aged 10-65 with Sickle Cell Disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Sickle cell disease

Recruiting

Study on the Safety and Effects of BMS-986470 for Patients with Sickle Cell Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986470
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cardiac valve disease

Recruiting

Study Comparing Apixaban and Carbasalate Calcium for Patients with Aortic Valve Replacement Due to Heart Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Creteil

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Groundbreaking studies focusing on TTR amyloidosis and heart disease treatments, evaluating novel therapeutic approaches for cardiac conditions. Research includes assessment of innovative medications for chronic kidney disease with hypertension.

  • TTR Amyloidosis Cardiomyopathy
  • Chronic Kidney Disease
  • Hypertension Management
02 Neurological Disorders

Comprehensive research into various neurological conditions, including innovative studies on Huntington's disease biomarkers and treatment approaches for essential tremor and Parkinson's disease.

  • Huntington's Disease Progression
  • Essential Tremor Treatment
  • Parkinson's Disease Management
03 Oncology & Hematology

Advanced clinical trials in blood cancers and solid tumors, including studies of multiple myeloma treatments and novel approaches for non-small cell lung cancer and mesothelioma.

  • Multiple Myeloma Therapies
  • Acute Myeloid Leukemia
  • Lung Cancer Treatment
04 Autoimmune Conditions

Innovative treatments for inflammatory and autoimmune disorders, investigating new therapies for Crohn's disease, ulcerative colitis, and rheumatoid arthritis.

  • Inflammatory Bowel Disease
  • Rheumatoid Arthritis Management
  • Microbiota Transplantation Studies
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.